Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
58.6M
-
Number of holders
-
139
-
Total 13F shares, excl. options
-
57.2M
-
Shares change
-
-98.1K
-
Total reported value, excl. options
-
$1.42B
-
Value change
-
-$4.96M
-
Put/Call ratio
-
1.37
-
Number of buys
-
60
-
Number of sells
-
-61
-
Price
-
$24.75
Significant Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (AGIO) as of Q3 2023
175 filings reported holding AGIO - AGIOS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share as of Q3 2023.
AGIOS PHARMACEUTICALS, INC. - Common Stock, $0.001 par value per share (AGIO) has 139 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 57.2M shares
of 58.6M outstanding shares and own 97.49% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (5.47M shares), WELLINGTON MANAGEMENT GROUP LLP (5.2M shares), BlackRock Inc. (4.65M shares), Bellevue Group AG (4.01M shares), ARMISTICE CAPITAL, LLC (3.32M shares), FARALLON CAPITAL MANAGEMENT LLC (2.75M shares), Rock Springs Capital Management LP (2.71M shares), JPMORGAN CHASE & CO (2.47M shares), DIMENSIONAL FUND ADVISORS LP (2.46M shares), and STATE STREET CORP (2.26M shares).
This table shows the top 139 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.